RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%
Bridgewater, NJ – January 8, 2026 – RVL Pharmaceuticals, Inc. and its affiliates (together, “RVL”) announces Santen Pharmaceutical Co., Ltd. (“Santen”), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids).
Read More